Average Co-Inventor Count = 3.55
ph-index = 10
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Cell Pathways (22 from 75 patents)
2. University of Arizona (4 from 972 patents)
3. Other (1 from 832,680 patents)
24 patents:
1. 6610854 - Substituted condensation products of N-benzyl-3-indenylacentamides with heterocyclic aldehydes for neoplasia
2. 6486158 - [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
3. 6455703 - 1,3,6,-Trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia
4. 6426349 - Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes for neoplasia
5. 6420410 - Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
6. 6403831 - Substituted benzylidene indenyl formamides, acetamides and propionamides
7. 6348032 - Method of inhibiting neoplastic cells with benzimidazole derivatives
8. 6300346 - Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
9. 6211177 - Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
10. 6180629 - [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
11. 6166053 - Substituted condensation products of N-benzyl-3-idenylacetamides with
12. 6160003 - 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment
13. 6121321 - Substituted methoxy benzylidene indenyl acetic and propionic acids for
14. 6071934 - Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating
15. 6066634 - Substituted condensation products of N-benzyl-3-indenylacetamides